Condition
HTLV-I-associated Myelopathy
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Terminated2
Unknown1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00272480Phase 2CompletedPrimary
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial
NCT00823641Phase 2TerminatedPrimary
The HAM Infliximab Study
NCT01343355Phase 2UnknownPrimary
Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
NCT00519181Not ApplicableTerminatedPrimary
Safety and Efficiency Study of Valproic Acid In HAM/TSP
Showing all 4 trials